Latin American licensed producer of medicinal cannabis and cannabis-derived products Blueberries Medical Corp. BBM BBRRF 1OA wrapped up 2023 with an announcement of a non-brokered private placement consisting of the sale of 180,716,00 common shares at CA$0.011 ($0.0083) per common share for aggregate gross proceeds of approximately CA$1,987,876.
The net proceeds from the sale of the common shares will be used to repay existing debt and for general corporate and working capital purposes.
The offering was led by Terraflos Inc., a company with operations throughout Latin America founded and controlled by Facundo Garreton, who serves as chairman, CEO and director of Blueberries.
Terraflos is exploring various prospects in Argentina, Mexico and Brazil with plans to expand operations into those markets in the short term.
See also: Exclusive: LatAm Cannabis Co. Terraflos, Founded By Former Congressman, Closes $8M Seed Funding Round
The company’s objective is to satisfy food and medicine needs using non-conventional methods, without exploiting natural resources as is common in current methodologies.
Earlier this year, Blueberries signed a joint venture agreement with Allied Corp. ALID. The collaboration includes the production of psychoactive and non-psychoactive derivatives.
By combining Allied's expertise in producing quality cannabis flowers with Blueberries' extraction facilities, the companies have joined forces in sales efforts, while optimizing production capabilities.
Related News
- Blueberries Medical Q2 Revenue Grows 169%, What About Net Loss?
- Blueberries Provides Corporate Update, Extends Maturity Date Of Convertible Debentures
- Blueberries Medical Reports Q1 2022 Financial Results, Eyes On Argentina’s New Medicinal Market
- Blueberries Medical Reports 110% Revenue Growth In 2021
BBRRF Price Action
Blueberries Medical's shares traded 12.7451% higher at $0.0138 per share after the market closed on Friday.
Missed the first wave of cannabis investments? Don't make that mistake again.
Experts believe cannabis stocks have found their floor and are now poised for unprecedented growth.
Join Benzinga PotProfits. Our in-house canna stock expert, Michael Berger, is on a mission to uncover the most promising cannabis stocks poised for growth, even in a dull market. He leaves no bud unturned to bring you the juiciest potential double-digit opportunities!
Just this year, the PotProfits portfolio has seen smoking-hot gains like:
- 47.10% with $GTBIF
- 40.23% with $TCNNF
- 21.50% with $VFF
But here's the kicker: Michael is about to release his next potential winners, and he's chomping at the bit to share these ticker symbols with you ASAP.
Don't miss out on the green rush!
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.